Edition:
United States

Antares Pharma Inc (ATRS.OQ)

ATRS.OQ on NASDAQ Stock Exchange Capital Market

2.39USD
16 Feb 2018
Change (% chg)

$0.04 (+1.70%)
Prev Close
$2.35
Open
$2.36
Day's High
$2.45
Day's Low
$2.22
Volume
620,907
Avg. Vol
414,654
52-wk High
$4.09
52-wk Low
$1.59

Chart for

About

Antares Pharma, Inc. (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs.... (more)
No analyst recommendations are available for .

Overall

Beta: 0.28
Market Cap(Mil.): €301.36
Shares Outstanding(Mil.): 156.41
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 34.52 17.27
EPS (TTM): -- -- --
ROI: -- 14.12 35.43
ROE: -- 16.75 17.10

BRIEF-Antares Pharma Provides Xyosted Regulatory Update

* ANTARES PHARMA INC - TYPE A MEETING HAS BEEN SCHEDULED WITH U.S. FOOD AND DRUG ADMINISTRATION ON FEBRUARY 21, 2018 FOR XYOSTED

Jan 16 2018

BRIEF-Antares Pharma Requests Type A Meeting With FDA Regarding Xyosted

* ANTARES PHARMA - WRITTEN REQUEST FOR A TYPE A MEETING HAS BEEN SUBMITTED TO FDA IN RESPONSE TO CRL RECEIVED REGARDING NDA FOR XYOSTED Source text for Eikon: Further company coverage:

Dec 21 2017

BRIEF-Antares Pharma Q3 loss per share $0.03

* Antares Pharma reports third quarter 2017 operating and financial results

Nov 07 2017

BRIEF-Antares Pharma receives complete response letter from FDA for Xyosted

* Antares pharma receives complete response letter from the fda for Xyosted

Oct 20 2017

BRIEF-Antares Pharma ‍says received FDA letter regarding deficiencies of its drug Xyosted

* Antares Pharma Inc - ‍anticipate receiving further clarification from FDA on or before prescription drug user fee act (PDUFA) date of October 20, 2017​

Oct 12 2017

BRIEF-Antares Pharma announces sale of Zomajet™ needle-free delivery system to Ferring Pharmaceuticals

* Antares Pharma announces sale of Zomajet™ needle-free delivery system to Ferring Pharmaceuticals

Oct 10 2017

Competitors

Earnings vs. Estimates

No consensus analysis data available.